Current partnerships

Genmab’s ability to quickly convert interesting disease targets into antibody therapeutics has attracted numerous partners. To maximize the value of our integrated human antibody development capabilities and our proprietary technology platforms, Genmab enters collaborations with other biotechnology and pharmaceutical companies to create or co-develop antibody products to novel disease targets.

Back to top

Amgen Inc.
Genmab has a direct license for exclusive worldwide rights to Amgen's  patent estate relating to antibodies to IL15 and the IL15 receptor. In July 2003, Amgen exercised its commercialization options for the HuMax®-IL15 antibody program (now AMG 714). Subsequently, in 2015, Amgen sub-licensed AMG 714 to a private company, Celimmune, LLC, which is now developing the product for nonresponsive and refractory celiac disease.

Novartis Pharma AG
Genmab and GlaxoSmithKline (GSK) entered a co-development and collaboration agreement for ofatumumab in 2006. The full rights to ofatumumab were subsequently transferred from GSK to Novartis in 2015. Novartis is now responsible for the development and commercialization of ofatumumab in all potential indications, including cancer and autoimmune diseases. Genmab is entitled to potential regulatory and sales milestones, in addition to double digit royalties. Novartis is fully responsible for all costs associated with developing and commercializing ofatumumab.

Janssen Biotech, Inc.
In August 2012, Genmab announced a global license and development agreement for daratumumab with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson. Under the terms of the agreement, Genmab granted Janssen an exclusive worldwide license to develop and commercialize daratumumab as well as a backup human CD38 antibody.

Genmab received an upfront license fee of $55 million (approx. DKK 327 million) and Johnson & Johnson Development Corporation (JJDC) invested DKK 475 million (approx. $80 million) to subscribe for 5.4 million new shares of Genmab at a price of DKK 88 per share. Genmab's closing share price on August 29, 2012, the day before the agreement was announced, was DKK 67.85. Genmab could also be entitled to up to $1 billion in development, regulatory and sales milestones, in addition to tiered double digit royalties. Janssen will be fully responsible for all costs associated with developing and commercializing daratumumab going forward.

The transaction became effective on September 21, 2012 after receiving clearance by the US antitrust authorities under the Hart-Scott-Rodino Act.

Bristol-Myers Squibb
In May 2012, Genmab licensed HuMax-IL8 to Cormorant Pharmaceuticals. Following the acquisition of Cormorant by Bristol-Myers Squibb (BMS), the HuMax-IL8 agreement was transferred to BMS. Under the terms of the agreement, Genmab received an upfront payment and will be entitled to milestone payments and royalties on net sales. BMS will be responsible for all future costs of developing, manufacturing and commercializing HuMax-IL8.  In May 2014 Genmab entered a research collaboration with Cormorant to evaluate our DuoBody® technology for the creation of a bispecific antibody against IL-8 and an undisclosed target. This agreement was also transferred to BMS as the result of their acquisition of Cormorant.

ADC Therapeutics Sarl
In June 2013, Genmab entered an agreement to develop a new antibody-drug conjugate (ADC) product combining Genmab's HuMax-TAC antibody with ADC Therapeutics' PBD-based warhead and linker technology.  Genmab and ADC Therapeutics will each initially have an equal share in the product. ADC Therapeutics will lead and fund pre-clinical development. Prior to submission of an IND filing, Genmab had the right to elect to retain equal ownership of the product. Genmab will not incur any development costs prior to the IND filing decision and will maintain a minimum 25% ownership stake in the product as it moves into clinical development.  In March 2015, Genmab decided not to exercise its co-development right for HuMax-TAC-ADC and now has a 25% ownership stake in the product.

Seattle Genetics, Inc.
In October 2011, Genmab and Seattle Genetics, Inc. entered into a commercial license and collaboration agreement for ADCs. Under the agreement, Genmab was granted rights to utilize Seattle Genetics ADC technology with its HuMax®-TF antibody. Seattle Genetics was granted rights to exercise a co-development and co-commercialization option at the end of Phase I clinical development for tisotumab vedotin. In 2017, Seattle Genetics exercised its option to co-develop tisotumab vedotin and the companies share all future costs and profits for the product on a 50:50 basis. Seattle Genetics will be responsible for commercialization activities in the US, Canada, and Mexico, while Genmab will be responsible for commercialization activities in all other territories. Each party has the option to co-promote by employing up to 40 percent of the sales effort in the other party's territories. 

Immatics Biotechnologies GmbH
In July 2018, Genmab and Immatics Biotechnologies GmbH (Immatics) entered into a research collaboration and exclusive license agreement to discover and develop next-generation bispecific immunotherapies to target multiple cancer indications. The deal combines Genmab's proprietary technologies and antibody know-how with Immatics' XPRESIDENT® targets and T-cell receptor (TCR) capabilities.  Genmab will receive an exclusive license to three proprietary targets from Immatics, with an option to license up to two additional targets at predetermined economics. The companies will conduct joint research, funded by Genmab, on multiple antibody and/or TCR-based bispecific therapeutic product concepts.

Genmab may elect to progress any resulting product candidates, and will be responsible for development, manufacturing and worldwide commercialization. For any products that are commercialized by Genmab, Immatics will have an option to limited co-promotion efforts in selected countries in the EU. Under the terms of the agreement, Genmab will pay Immatics an upfront fee of USD 54 million and Immatics is eligible to receive up to USD 550 million in development, regulatory and commercial milestone payments for each product, as well as tiered royalties on net sales.

BliNK Biomedical
In July 2019, Genmab and BliNK Biomedical entered into an exclusive commercial license to certain antibodies targeting CD47, for potential development and commercialization into novel bispecific therapeutics created via Genmab’s proprietary DuoBody Platform technology. Under the terms of the agreement, Genmab will pay BliNK Biomedical an upfront fee of USD 2.25 million. BliNK Biomedical is also eligible to receive up to approximately USD 200 million in development, regulatory and commercial milestone payments for each product, as well as tiered royalties on net sales.

CureVac AG
In December 2019, Genmab and CureVac AG entered into a research collaboration and license agreement. The companies will collaborate on research to identify an initial product candidate, followed potentially by three additional programs, combining CureVac’s mRNA technology and know-how with Genmab’s proprietary antibody technologies and expertise. Under the terms of the agreement Genmab will provide CureVac with an upfront payment, an equity investment in CureVac and CureVac will be eligible to receive certain milestone and royalty payments from Genmab per product, depending on product concept.

Back to top

Medarex
Genmab has a unique alliance with Medarex, a wholly owned subsidiary of Bristol-Myers Squibb, which provides access to the UltiMAb® system for creating the full range of human antibody isotypes. Under this agreement, Genmab has the right to obtain licenses for an unlimited number of antibodies and owns the worldwide development and commercialization rights to these products. Genmab’s principal obligation under this agreement is to make milestone and royalty payments in connection with any such product licenses. Genmab received these rights in exchange for stock in the company, in addition to 16 fully paid up product licenses, which require no further payments to Medarex.

Seattle Genetics
In September 2010, Genmab and Seattle Genetics, Inc. entered into an antibody-drug conjugate (ADC) research collaboration agreement. Under the agreement, Genmab has rights to utilize Seattle Genetics’ ADC technology with its HuMax®-TF antibody and Seattle Genetics has the right to exercise a co-development option for any resulting ADC products at the end of Phase I clinical development.  In 2017, Seattle Genetics exercised its option to co-develop tisotumab vedotin (an ADC composed of Genmab's HuMax-TF antibody Seattle Genetics' ADC technology that utilizes a cleavable linker and the cytotoxic drug monomethyal auristatin E (MMAE)).

In April 2011, Genmab entered into a second ADC research collaboration agreement with Seattle Genetics. Under the new agreement, Genmab has rights to utilize Seattle Genetics’ ADC technology with HuMax®-CD74, an antibody in pre-clinical development to target CD74, which is expressed on a wide range of hematological malignancies and solid tumors. Seattle Genetics has the right to exercise a co-development and co-commercialization option for any resulting ADC products at the end of Phase I clinical development. Genmab discontinued development of HuMax-CD74-ADC in the first quarter of 2013.

For both programs, Genmab is responsible for research, manufacturing, pre-clinical development and Phase I clinical evaluation of HuMax®-ADCs. Seattle Genetics will receive research support payments for any assistance provided to Genmab. If Seattle Genetics opts into a HuMax-ADC product at the end of Phase I, a payment would be due to Genmab and the companies would co-develop and share all future costs and profits for the product on a 50:50 basis. If Seattle Genetics does not opt in to a HuMax-ADC product, Genmab would pay Seattle Genetics fees, milestones and mid-single digit royalties on worldwide net sales of the product.

In September 2014, Genmab entered into an additional ADC collaboration with Seattle Genetics. Under this collaboration, Genmab paid an upfront fee of $11 million for exclusive rights to utilize Seattle Genetics' ADC technology with Genmab's HuMax-AXL antibody.  Seattle Genetics is also entitled to receive more than $200 million in potential milestone payments and mid-to-high single digit royalties on worldwide net sales of any resulting products. In addition, prior to Genmab's initiation of a Phase III study for any resulting products, Seattle Genetics has the right to exercise an option to increase the royalties to double digits in exchange for a reduction of the milestone payments owed by Genmab. Irrespective of any exercise of option, Genmab remains in full control of development and commercialization of any resulting products.

Novartis
In June 2012, Genmab entered an agreement with Novartis to use our DuoBody® technology platform to create and develop panels of bispecific antibodies to two disease target combinations identified by Novartis. All research work on the programs is fully funded by Novartis.

Under the terms of the agreement, Genmab received an upfront payment of $2 million (approx. DKK 12 million). If all milestones in the agreement are achieved, the total potential value of the agreement to Genmab would be approximately $175 million (approx. DKK 1,055 million), plus research funding and royalties.

Janssen
In July 2012, Genmab entered into a collaboration with Janssen Biotech, Inc. to create and develop bispecific antibodies using our DuoBody technology platform.  Genmab will create panels of bispecific antibodies to multiple disease target combinations identified by Janssen, who will in turn fully fund research at Genmab.  

Under the terms of the agreement, Genmab and Janssen will collaborate on the research of up to 10 DuoBody programs and Genmab received an upfront payment of $3.5 million (DKK 21 million) from Janssen and all research by Genmab will be fully funded by Janssen. In addition, Genmab will potentially be entitled to milestone and license payments of up to approximately $175 million (DKK 1,062 million) for each product as well as royalties on any commercialized products.

In December 2013, Genmab expanded their DuoBody collaboration.  Under the terms of the collaboration amendment, Janssen is entitled to work on up to ten additional programs.  Genmab received an initial payment of $2 million (DKK 11 million) from Janssen.  For each of the ten additional programs that Janssen successfully initiates, develops and commercializes, Genmab will potentially be entitled to milestone and license payments of up to approximately $174 million (DKK 956 million) to $219 million (DKK 1.2 billion), depending on the date each program is initiated. In the most favorable scenario in which all ten additional programs are successfully initiated, developed and commercialized, Genmab would receive average milestone and license payments of approximately $191 million (DKK 1.0 billion ) for each of the ten programs. In addition, Genmab will be entitled to royalties on sales of any commercialized products.

Agenus Inc.
In June 2014, Genmab entered a new research collaboration in immuno-oncology with Agenus Inc. under which Agenus and its affiliates, including 4-Antibody AG will use Genmab's DuoBody technology to create bispecific antibodies against immune checkpoint targets. The financial terms of the agreement were not disclosed.

Humabs BioMed
In October 2014, Genmab entered a research evaluation agreement with Humabs BioMed, a Swiss biotech company, which will evaluate the HexaBody and DuoBody platforms. The financial terms of the agreement were not disclosed.

BioNTech
In May 2015, Genmab entered an agreement with BioNTech AG to jointly research, develop and commercialize bispecific antibody products using Genmab's DuoBody technology platform. Under the terms of the agreement, BioNTech will provide proprietary antibodies against key immunomodulatory targets that play an important role in activating the immune system against cancer, while Genmab provides access to its DuoBody technology platform. Genmab will pay an upfront fee of USD 10 million to BioNTech and additional potential near-term payments of up to USD 5 million if certain BioNTech assets are selected for further development. If the companies jointly select any product candidates for clinical development, development costs and product ownership will be shared equally going forward. If one of the companies does not wish to move a product candidate forward, the other company is entitled to continue developing the product on predetermined licensing terms. The agreement also includes provisions which will allow the parties to opt out of joint development at key points.

Novo Nordisk
In August 2015, Genmab entered an agreement to grant Novo Nordisk commercial licenses to use the DuoBody technology platform to create and develop bispecific antibody candidates for two therapeutic programs outside of cancer therapeutics. After an initial period of exclusivity for the two target combinations, Novo Nordisk has an option to maintain exclusivity or take the licenses forward on a non-exclusive basis. 

Under the terms of the agreement, Genmab received an upfront payment of $2 million. Genmab is entitled to potential development, regulatory and sales milestones of up to approximately $250 million for each exclusive license, or approximately $200 million for each non-exclusive license. In addition, Genmab will be entitled to single-digit royalties on sales of any commercialized products.
  

Back to top

Roche
In May 2001, Genmab entered a collaboration with Roche to develop human antibodies to disease targets identified by Roche. In 2002, this alliance was expanded and Roche made an equity investment in Genmab totaling $20 million. Under the agreement, Genmab will receive milestones as well as royalty payments on successful products and in certain circumstances Genmab could obtain rights to develop products based on disease targets identified by Roche.

H. Lundbeck A/S
Genmab and H. Lundbeck A/S entered an agreement to create and develop human antibody therapeutics for disorders of the central nervous system (CNS) in October 2010. Genmab will create novel human antibodies to three targets identified by Lundbeck. Lundbeck will have access to Genmab’s antibody creation and development capabilities, including its UniBody® platform. Lundbeck will have an option to take selected antibodies into clinical development at its own cost and subject to the payment of milestones and single-digit royalties to Genmab upon successful development and commercialization. Genmab will have a similar option to take selected antibodies into clinical development for cancer indications at its own cost and subject to the payment of milestones and single-digit royalties to Lundbeck.

Under the terms of the agreement, Genmab received an upfront payment of €7.5 million (approximately DKK 56 million). Lundbeck will fully fund the development of the antibodies. If all milestones in the agreement are achieved, the total value of the agreement to Genmab would be approximately €38 million (approximately DKK 283 million), plus single-digit royalties.

Tempus
In September 2019, Genmab entered into a collaboration agreement with Tempus, which built upon existing service agreements between the companies. Under the terms of the collaboration agreement, the companies will jointly work on research projects that are identified by Genmab to explore novel product concepts and biomarkers. For any resulting products, Genmab will lead all development and commercial activities. Tempus will be eligible for undisclosed milestones and royalties from Genmab and will also have the option to fund part of product development programs in exchange for increased royalty payments due to Tempus under the agreement.

Back to top